Edward Chu MD

Deputy Director, Cancer Center; Chief, Section of Medical Oncology

Departments & Organizations

Yale Medical Group

Cancer Prevention and Control Center

Developmental Therapeutics

Research Interests

Developmental therapeutics, cancer drug resistance, translational regulation, RNA-protein interactions, colorectal cancer, GI cancers, cancer drug development. more...

Education

• M.D., Brown University, 1983

Selected Publications

• Ju, J., Schmitz, J.C., Song, B., Kudo, K., and Chu, E: Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. Clin Cancer Res 13, 4245-4251, 2007. Schmitz, J.C., Tai, N., and Chu, E. Translational autoregulation of thymidylate synthase and dihydrofolate reductase and therapeutic implications. Frontiers in Biosciences, 2007. Chu, E. and DeVita, V.T.: Principals of Chemotherapy. In: DeVita, V.T., Lawrence, T., and Rosenberg, S.A. (Eds.), Cancer: Principles and Practice of Oncology, Eighth Edition, J.B. Lippincott Co., Philadelphia, 2008 Chu, E. and Cartwright T.H.: The pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer. J Clin Oncol, 26, 2224-2226, 2008. DeVita, V.T. Jr., Chu, E.: A history of cancer chemotherapy. Cancer Res 68, 8643-8653, 2008. Saif, M.W., Choma, A., Salamone, S.J., and Chu, E.: Pharmacokinetically-guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst, in press, 2009.

more...